Grey Wolf Therapeutics is a UK-based biotechnology company focused on developing novel immuno-oncology agents. The company was founded in 2017 by experienced industry professionals; Tom McCarthy (Executive Chairman), former President and CEO of Spinifex Pharmaceuticals and Peter Joyce (CEO), former Project Leader at Vertex Pharmaceuticals.
Rather than targeting the immune system, Grey Wolf’s approach is to directly alter tumour cells, illuminating them for attack and destruction by the immune system. The company is developing small molecules that inhibit the endoplasmic reticulum aminopeptidases (ERAP1 and ERAP2), which play a key role in the antigen presentation pathway. Grey Wolf has demonstrated that inhibiting these enzymes leads to modulation of the antigen repertoire within tumour cells, dramatically increasing tumour visibility and extending the reach of immunotherapy in oncology.
Grey Wolf is working with leading academic and commercial drug discovery partners to deliver first-in-class clinical candidates against strongly validated targets. The core team is strengthened by a network of collaborations with experts in immuno-oncology, antigen presentation and drug discovery across world leading academic institutions, including The University of Oxford and University of Southampton.
Grey Wolf is a preclinical stage company executing on multiple programs that are all focused on harnessing the potential of targeting ERAP as a differentiated and innovative approach to modulate tumour visibility in immuno-oncology.
Grey Wolf Therapeutics is a private company supported by investors committed to delivering next generation oncology therapies.